Analyst Targets Signal Potential Upside for FSMD ETF

The Fidelity Small-Mid Multifactor ETF (FSMD) suggests a potential 13.82% upside according to analyst targets. This raises questions on the sustainability of these estimates amid recent trading activity.

Date: 14-05-2025

AI Rating: 7

Potential Upside in Analyst Targets
The Fidelity Small-Mid Multifactor ETF (FSMD) displays a significant potential upside as it trades at $40.87 against an implied analyst target of $46.52. This suggests a 13.82% potential increase. Investors should consider whether this target is realistic or indicative of over-optimism.

Underlying Holdings Performance
Among FSMD's holdings, Halozyme Therapeutics Inc (HALO) shows the highest target increase potential, with analysts predicting a 40.11% rise from its recent price of $50.23 to a target of $70.38. Waystar Holding Corp (WAY) is estimated to rise 24.59% from $39.11 to $48.73, while QCR Holdings Inc (QCRH) has a 19.74% upside expected from $70.82 to $84.80. These anticipated increases indicate strong confidence in the growth prospects of these companies.

Investor Considerations
While high target prices could signify analyst optimism about future performance, they may also signal vulnerability to downgrades if expectations aren’t met in a changing market. Analysts' confidence in the upward trend must be examined against recent developments in these sectors. Further detailed analysis may be warranted to assess whether analysts are aligned with contemporary market dynamics or lagging behind. Overall market conditions and the financial performance of individual holdings will be essential to reevaluating these targets.

Stocks: FSMD HALO WAY QCRH